Outlook Therapeutics Stock Jumps as FDA Accepts Lytenava BLA, July Decision Looms

Outlook Therapeutics, Inc. stock surged Tuesday after the company said the U.S. Food and Drug Administration accepted its resubmitted Biologics License Application, or BLA, for ONS-5010/LYTENAVA as a treatment for wet age-related macular degeneration. A BLA is the FDA application used to seek approval to market a biologic medicine. OTLK traded at $1.51, up about 30.2% from its previous close of $1.16, with intraday volume above 33.7 million shares, according to market data available in afternoon trading.

16 June 2026

CervoMed Shares Rise in Early Trade After $3 Million Insider-Related Purchase

CervoMed Inc. shares spiked in premarket trading Tuesday, quoted around $3.30 after closing at $2.48 on Monday. The stock was up more than 30%, with MarketScreener and MT Newswires tying the jump to an SEC filing late Monday. The pop wasn’t about new clinical news. Instead, it followed a show of insider confidence: a Form 4 showed the Joshua S. Boger 2021 Trust bought 955,414 units at $3.14 apiece in a private placement, totaling about $3 million. Private placements are limited sales to select investors, not the public.

16 June 2026

NASDAQ:CRVO·Pharmaceuticals·Stock Market

Pfizer Holds Near $26, Dividend Draws Watch as Drug Prices Cloud Outlook

Pfizer Inc. ended the U.S. session at $26.21, up 4 cents. Volume was around 38.8 million shares and market cap was close to $150.2 billion. Shares barely budged even as the S&P 500 gained 0.50% and the Dow added 0.70%, according to market data. Pfizer’s trailing P/E hovered near 20.

15 June 2026

Dividends·NYSE:PFE·Pharmaceuticals·Stock Market

Pfizer trades around $26 with dividend in focus, drug-price worries linger

Pfizer Inc. closed Friday at $26.21, up 4 cents. About 38.77 million shares changed hands. Market cap came in near $149.38 billion. Gains were small against the major indexes. The S&P 500 added 0.5%, Dow rose 0.7%, and Nasdaq was up 0.3%. The Health Care Select Sector SPDR ETF dropped 0.18%. Pfizer still outperformed its sector benchmark.

13 June 2026

Dividends·NASDAQ:BNTX·NYSE:PFE·Pharmaceuticals·Stock Market

Alumis Shares Surge 16% as Traders Eye New Drug Move

Alumis Inc. jumped 15.55% Friday, finishing at $24.15 on Nasdaq—up $3.25. Volume hit about 2.25 million shares, more than double its typical 1.01 million average. Market cap climbed to $3.08 billion. The stock moved closer to its 52-week high of $30.60, according to Google Finance.

12 June 2026

NASDAQ:ALMS·Pharmaceuticals·Stock Market

Pfizer Stock Had a Quiet Week. Its Cancer Pipeline Just Got Loud

Pfizer Still Trades Over $26 as RBC Lift Balances Out Drug-Pricing Concerns

Pfizer Inc. shares added 0.36% to trade around $26.27 Friday, putting its market cap at roughly $150.5 billion. The stock had climbed 2.23% Thursday, closing at $26.17, on higher-than-average volume and outperforming most major health-care names, MarketWatch said. Broader markets were higher Friday, with the SPDR S&P 500 ETF Trust up, but the Health Care Select Sector SPDR ETF was down a bit, showing Pfizer trading better than the sector in late-morning deals.

12 June 2026

NYSE:PFE·Pharmaceuticals·Stock Market

Pfizer Shares Edge Higher on RBC Upgrade, German Pricing Risk in Focus

• Pfizer stock rose about 2.7% to around $26.28 in late Thursday trading.• RBC Capital moved its rating on Pfizer up to Sector Perform from Underperform, sticking with the $25 target.• Reuters said new German drug-pricing plans are adding another risk for global pharma companies.

11 June 2026

NYSE:PFE·Pharmaceuticals·Stock Market

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

Theriva Biologics, Inc. shares surged Thursday after news that data from a Phase 1 trial of its main cancer drug VCN-01 appeared in Clinical Cancer Research. Traders jumped on TOVX, which last traded at $0.4252, up 74.6%. Volume was 144.7 million shares. Theriva’s market cap is still under $20 million, at about $17.0 million.

11 June 2026

NASDAQ:TOVX·Pharmaceuticals·Stock Market

Parabilis Medicines (PBLS) soars 58% after $670 million IPO beats range

Parabilis Medicines jumped in its Nasdaq debut Wednesday. Shares opened under PBLS and closed at $31.60, up 58% from the $20 IPO price. The company had priced a bigger-than-expected $670 million initial offering, topping the marketed range. Investors chased the deal harder than Parabilis suggested just a day before.

10 June 2026

IPO News·NASDAQ:PBLS·Pharmaceuticals·Stock Market

Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

Nuvalent is trading on deal odds now, not on drug data. Shares last traded at $123.25, up 39.28%, after GSK said it will buy the Nasdaq-listed biotech for $124 per share in cash. That leaves just a small discount to the offer price. Nuvalent’s stock is being valued more like a GSK takeover play than an oncology bet.

10 June 2026

Mergers and Acquisitions·NASDAQ:NUVL·NYSE:GSK·Pharmaceuticals·Stock Market

Roche Shares Edge Up After $2.3 Billion Nurix Cancer Pact

Roche Holding Ltd. participation certificates listed on SIX traded up 1.07% at CHF 322.20 late Wednesday morning. Investors were eyeing a new $2.3 billion deal with Nurix Therapeutics, bringing Roche a late-stage blood-cancer asset. The stock line now trades as ROP after the company switched from the former ROG Genussscheine in March. Roche’s bearer shares are listed as RO.

10 June 2026

Pharmaceuticals·Stock Market·SWX:ROP

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK is set to acquire U.S.-based Nuvalent for $10.6 billion in cash, making it the largest deal GSK has made in years. The offer is $124 per share, which works out to a 40% premium on Nuvalent’s previous closing price. It’s an early move by CEO Luke Miels as he looks to revamp the British group’s oncology pipeline.

9 June 2026

LSE:GSK·NASDAQ:NUVL·Pharmaceuticals

Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

Pfizer Inc. shares fell in premarket trading Tuesday after the FDA cleared a new label for its hemophilia treatment Hympavzi. Investors are still sizing up the company’s longer path to profits in obesity drugs. The stock traded at $25.62, off 43 cents, or 1.7%.

9 June 2026

NYSE:PFE·Pharmaceuticals·Stock Market

Why Novo Nordisk Stock Fell Even After Wegovy Pill Hit 3 Million Prescriptions

Novo Nordisk’s Copenhagen-listed B shares fell 4.2% to DKK 272.00 after Monday’s session, underperforming a 0.9% drop in the OMX Copenhagen 25, even as the Danish drugmaker reported another strong demand marker for its Wegovy pill. Its U.S.-listed shares were at $41.02, down about 4.6%.

9 June 2026

NASDAQ:NVO·Pharmaceuticals·Stock Market

Nurix Shares Jump Premarket on Roche $2.3 Billion Cancer Drug Deal

Nurix Therapeutics shares surged in premarket trading Monday after Roche said it will pay $700 million upfront for development and commercialization rights to bexobrutideg, Nurix’s experimental drug for blood cancers and immune diseases. The stock, listed on Nasdaq, traded at $17.62 at 8:00 a.m. ET, up 20.4% from Friday’s close.

8 June 2026

NASDAQ:NRIX·Pharmaceuticals·Stock Market

Eli Lilly Stock Sets High Ahead of Monday Data

Eli Lilly shares finished the week at a record high close, gaining 0.6% Friday at $1,131.42. On Saturday, the company put out late-stage results showing its retatrutide injection, still experimental, cut obstructive sleep apnea severity by 60.6% and reduced knee osteoarthritis pain by as much as 73.1% in obese adults.

6 June 2026

Earnings Reports·NYSE:LLY·Pharmaceuticals·Stock Market

Veru Shares Pop on Novo Wegovy Tie-Up, Uncertainty Lingers Over Key Clause

Veru Inc. shares stayed active premarket Friday as the biotech said it has a supply deal with Novo Nordisk tied to a weight-loss study using Wegovy. Benzinga data had the stock at $3.70 before the open at 7:01 a.m. ET. The move followed Thursday’s rally, when it closed at $4.23, up 88% for the day.

5 June 2026

NASDAQ:VERU·NYSE:NVO·Pharmaceuticals·Stock Market

Merck Stock Gains as Keytruda Concerns Ease, Investors Look to Pipeline Bets

Merck & Co. shares climbed 4.9% to $120.26 late Thursday, adding $5.59 and putting the drugmaker among the top movers in a Dow rally paced by healthcare stocks. UnitedHealth and Merck made up about a third of the Dow’s gains earlier in the day, MarketWatch said.

4 June 2026

NYSE:MRK·Pharmaceuticals·Stock Market

Pfizer Stock Had a Quiet Week. Its Cancer Pipeline Just Got Loud

Pfizer Inc. heads into Monday’s open with investors facing a heavier cancer-drug news tape than its stock price showed last week, after fresh oncology data at the American Society of Clinical Oncology meeting and a China partnership worth up to $10.5 billion.

31 May 2026

NYSE:PFE·Pharmaceuticals

Oculis Stock Shock: Eye-Drop Trial Miss Sends Shares Sliding

Oculis Holding AG shares fell sharply on Friday after the Swiss eye-drug developer said two late-stage trials of its OCS-01 eye drops failed to meet their main goal in diabetic macular edema, a diabetes-linked swelling in the retina that can damage sight. The company said it does not currently plan to pursue a U.S. Food and Drug Administration filing for the drug in that indication.

30 May 2026

NASDAQ:OCUL·Pharmaceuticals·Stock Market